Always Remember - Buy The Dip

If you have trouble remembering please watch the video below. Definitely some language.

Sentiment Analysis For OPHT

The news is currently generally neutral for OPHT.

Based on TextBlob analysis of Yahoo! Finance news summaries for OPHT on 2015-08-05.

Yahoo! Finance News for OPHT

Will Ophthotech (OPHT) Continue to Surge Higher? - Tale of the Tape
Ophthotech Corp ( OPHT ) has been on the move lately as the stock has risen by 32.5% in the past four weeks, and it is currently trading well above its 20 Day SMA. This is a pretty solid

3 Tiny Stocks to Buy If Biotech Tumbles
Source Flickr user Since 2012, biotechnology stocks have tripled the return of the broader S&P 500 a stunning return that has caught many investors flat footed. But

Ophthotech (OPHT) is Overbought: Is A Drop Coming? - Tale of the Tape
Ophthotech Corporation ( OPHT ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because OPHT is now in overbought territory with an RSI value of 82.27. What

5 Drugs That Investors May Be Undervaluing
Source Flickr user Attaching a dollar value to a biotech stock's clinical trial pipeline is one if not the most vexing challenge facing biotech

Pop! 3 To Buy If Biotech Stocks Burst
Source Flickr user Andrew Magill. Biotechnology has been one of the best performing industries over the past two years, but a flood of venture capital and IPOs, and a big run

Commit To Buy Ophthotech Corp At $40, Earn 8.1% Annualized Using Options
Investors eyeing a purchase of Ophthotech Corp (Symbol OPHT) shares, but cautious about paying the going market price of $52.01 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in

Will AVEO Pharmaceuticals (AVEO) Surprise This Earnings? - Analyst Blog
AVEO Pharmaceuticals, Inc.AVEO is expected to report first quarter 2015 results on May 6. AVEO's performance in 2014 has been impressive with the company beating expectations in three of the four trailing quarters with an average positive earnings surprise

AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog
On Apr 14, Zacks Investment Research upgraded AVEO Pharmaceuticals, Inc.AVEO to a Zacks Rank #1 (Strong Buy).Why the Upgrade? AVEO put up a standard performance in 2014, delivering positive earnings surprises in three of the last four quarters with

3 Little-Known Biotechs Working On Potential Blockbusters
Biotech stocks are prone to jaw dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors.

3 Little-Known Stocks I'm Glad I Bought
Source Flickr user Investing in clinical stage biotech stocks isn't for the faint of heart. The industry's jaw dropping pops and drops can be so dramatic as to suit these

2 Tiny Biotechs That Could Have Blockbuster Opportunity
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog
Celgene Corporation ( CELG ) announced that Revlimid has received approval from the European Commission for the treatment of adults with previously untreated multiple myeloma who are not eligible for transplant. Shares were up 2.5% on the news. The

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog
Updates on the regulatory front are eagerly awaited by investors in the pharma biotech sector as they impact the share price of the concerned company. Regulatory updates include events like filing of marketing applications, acceptance of these applications for

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog
Coronado Biosciences, Inc. ( CNDO ) announced that it has exclusively licensed a late stage intravenous (IV) formulation of tramadol for the U.S. market from a privately held pharmaceutical company, Revogenex Ireland Ltd. Coronado informed that the tramadol license

Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Alnylam Pharmaceuticals, Inc. 's ( ALNY ) fourth quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year ago loss of 51 cents per